EDITAS MEDICINE, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
EDITAS MEDICINE, INC. (EDIT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $793.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-05
- EDITAS MEDICINE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- EDITAS MEDICINE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $793.00K, a 3.52% increase year-over-year.
- EDITAS MEDICINE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- EDITAS MEDICINE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- EDITAS MEDICINE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $766.00K, a 3.53% decline from fiscal 2024.
- EDITAS MEDICINE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $794.00K, a 71.15% decline from fiscal 2023.
- EDITAS MEDICINE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.75M, a 88.79% decline from fiscal 2022.
- EDITAS MEDICINE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $24.55M, a 128.62% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $793.00K 10-Q · filed 2026-08-05 | $793.00K derived: sum of 3 quarters · filed 2026-08-05 | $793.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $793.00K 10-Q · filed 2026-05-05 | $793.00K derived: sum of 2 quarters · filed 2026-05-05 | $793.00K derived: sum of 3 quarters · filed 2026-05-05 | $793.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $766.00K 10-K · filed 2026-03-09 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $766.00K 10-Q · filed 2025-11-10 | $766.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $766.00K 10-Q · filed 2026-08-05 | $766.00K derived: sum of 3 quarters · filed 2026-08-05 | $766.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $766.00K 10-Q · filed 2026-05-05 | $766.00K derived: sum of 2 quarters · filed 2026-05-05 | $766.00K derived: sum of 3 quarters · filed 2026-05-05 | $766.00K derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $794.00K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $794.00K 10-Q · filed 2025-11-10 | $2.48M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $794.00K 10-Q · filed 2025-08-12 | $2.48M derived: sum of 3 quarters · filed 2025-08-12 | $2.48M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $794.00K 10-Q · filed 2025-05-12 | $2.48M derived: sum of 2 quarters · filed 2025-05-12 | $2.48M derived: sum of 3 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $1.68M derived: sum of 2 quarters · filed 2025-03-05 | $2.75M 10-K · filed 2025-03-05 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.07M 10-Q · filed 2023-11-03 | |||
| 2023-06-30 | $1.07M 10-Q · filed 2023-08-02 | ||||
| 2022-12-31 | $19.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $24.55M 10-K · filed 2025-03-05 | $29.86M 10-K · filed 2023-02-22 | ||
| 2022-09-30 | $4.71M 10-Q · filed 2023-11-03 | ||||
| 2021-12-31 | $983.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $983.00K derived: sum of 2 quarters · filed 2024-02-28 | $10.74M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $9.75M 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | $9.75M 10-Q · filed 2022-08-03 | ||||
| 2020-06-30 | $3.32M 10-Q · filed 2021-08-05 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $19.46M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $19.46M 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $19.46M 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $19.46M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |